Systemic therapy of androgenic alopecia

Cover Page

Abstract


The article describes the literature sources related to the efficacy of systemic therapy of androgenic alopecia in female and male.

I. N. Kondrakhina

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru

Russian Federation

A. N. Mareeva

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: nastasya_66@mail.ru

Russian Federation

  1. Tosti A., Piraccini B., Sisti A. et al. Hair loss in women. Minerva Ginecol 2009; 61: 445-452.
  2. Kelekci K.H, Kelekci S. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. J Dermatolog Treat. 2012 Jun; 23 (3): 177-83.
  3. Vexiau P., Chaspoux C., Boudou P. et al. Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia: A controlled, 12-month randomized trial. Br J Dermatol 146: 992-999, 2002.
  4. Brzezinska-Wcislo L. Assessment of efficacy of Diane-35 in androgenetic feminine alopecia. Wiad Lek, 2003. 56: 202-5.
  5. Lucky A.W., Piacquadio D.J., Ditre C.M. et al. A randomized, placebocontrolled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol, 2004, 50: 541-53.
  6. Алейникова Н.Л., Мазитова Л.П., Чернуха Г.Е. Сравнительная эффективность антиандрогенных препаратов в лечении андрогенетической алопеции женщин репродуктивного возраста. Экспериментальная и клиническая дерматокосметология 2004; 6: 38-40.
  7. Мареева А.Н. Оптимизация тактики ведения женщин репродуктивного возраста с андрогенетической алопецией с учетом уровня стероидных гормонов и молекулярно-генетических факторов. Автореферат диссертации на соискание ученой степени кандидата медицинских наук. М. 2013.
  8. Sinclair R., Wewerinke M., Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol, 2005, 152: 466-73.
  9. Rathnayake D., Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010 Jul; 28 (3): 611-8.
  10. Carmina E., Lobo N. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003, 79: 91-5.
  11. Paradisi R., Porcu E., Fabbri R. et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011 Apr; 45 (4): 469-75.
  12. Ong K., F. de Zegher, López-Bermejo A. et al. Flutamide-metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype. European Journal of Endocrinology, 2007: Vol. 157, Issue 5: 661-668.
  13. Kaufman K.D., Olsen E.A., Whiting D. et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol, 1998, 39: 578-89.
  14. Price V.H., Roberts J.L., Hordinsky M. et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-76.
  15. Shum K.W., Cullen D.R., Messenger A.G. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002; 47: 733-9.
  16. Thai K.E., Sinclair R.D. Finasteride for female androgenetic alopecia. Br J Dermatol 2002; 147: 812-13.
  17. Trüeb R.M. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004, 209: 202-7.
  18. Oliveira-Soares R., Maia e Silva J., Peres Correia M. Finasteride 5 mg/day reatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. Int J Trichology. 2013 Jan-Mar; 5 (1): 22-25.
  19. Boersma I.H., Oranje A.P., Grimalt R. et al. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014 Nov-Dec; 80 (6): 521-5.
  20. Vexiau P., Chaspoux C., Boudou P. et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res. 2000 Dec; 292 (12): 598-604.
  21. Shapiro J., Kaufman K.D. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Invest Derm Symp Proc 2003: 8: 20-23.
  22. Kaufman K.D., Girman C.J., Round E.M. et al. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol 2008: 18: 407-411.
  23. Kaufman K.D, Rotonda J., Shah A.K. et al. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008: 18: 400-406.
  24. Olsen E.A., Hordinsky M., Whiting D. et al. Dutasteride Alopecis Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006: 55: 1014-1023.
  25. Eun H.C., Kwon O.S., Yeon J.H. et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebocontrolled, phase III study. J Am Acad Dermatol. 2010 Aug; 63 (2): 252-8.
  26. Gubelin Harcha W., Barboza Martinez J., Tsai T.F. et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar; 70 (3): 489-498.
  27. Jung J.Y., Yeon J.H., Choi J.W. et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014 Nov; 53 (11): 1351-7.

Views

Abstract - 73

PDF (Russian) - 64

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies